Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07181837 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
A Phase 1 study of Angelman Syndrome, sponsored by MavriX Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT07181837: Recruiting Phase 1 study of Angelman Syndrome, sponsored by MavriX Bio.
NCT07181837 is a Phase 1 study of Angelman Syndrome that is actively recruiting participants, run by MavriX Bio. The registered enrollment target is 12 participants, below the 125-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07181837, a Phase 1 study of Angelman Syndrome, is actively recruiting participants, sponsored by MavriX Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
Conditions Studied
Interventions
- GENETIC MVX-220
Study Locations (3)
California
- Cedars-Sinai Medical Center - Los Angeles
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2031-05-31 |
| Phase | Phase 1 |
What NCT07181837 shows while recruiting
NCT07181837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 125-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 1 intervention - of which MVX-220 is the first listed.
NCT07181837 reports a single indexed study location in California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07181837 about?
NCT07181837 is a clinical study titled "A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome". The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
What is the current status of trial NCT07181837?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-10-29. Estimated completion is 2031-05-31.
What conditions does trial NCT07181837 study?
This clinical trial studies the following conditions: Angelman Syndrome.
What interventions are being tested in trial NCT07181837?
The interventions under investigation include: MVX-220 (GENETIC).
Who is sponsoring clinical trial NCT07181837?
This trial is sponsored by MavriX Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07181837 being conducted?
This trial has 3 study locations across California, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07181837's enrollment target sits among peer trials
12 12th of 11 the lowest of 11 other Angelman Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Angelman Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
COMPLETED · Phase 1
-
Angelman Syndrome Natural History Study
RECRUITING
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RECRUITING · Phase 3
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI